Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on MiMedx Group (NASDAQ:MDXG) and maintained a price target of $11.
August 01, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on MiMedx Group (NASDAQ:MDXG) and maintained a price target of $11.
The reiteration of an Overweight rating and a maintained price target of $11 by a reputable analyst can boost investor confidence in MiMedx Group, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100